Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
AIMS: This ancillary analysis of the GISSI-HF database aims at assessing the effect of rosuvastatin on the occurrence of atrial fibrillation (AF) in patients with chronic heart failure (HF) who were not in AF at study entry. METHODS AND RESULTS: GISSI-HF was a double-blind, placebo-controlled trial testing n-3 PUFA and rosuvastatin vs. corresponding placebos in patients with chronic HF. Atrial fibrillation occurrence was defined as the presence of AF in the electrocardiogram (ECG) performed at each visit during the trial or AF as a cause of worsening HF or hospital admission or as an event during hospitalization. Among the 3690 patients (80.7%) without AF on their baseline ECG, 15.0% developed AF during a median follow-up period of 3.7 years, 258 randomized to rosuvastatin (13.9%) vs. 294 allocated to placebo (16.0%). Although the difference was not significant at unadjusted analysis (P = 0.097) and multivariable analysis adjusting for clinical variables (P = 0.067), it became significant after adjustment for clinical variables and laboratory examinations (P = 0.039), and for clinical variables, laboratory examinations, and background therapies (P = 0.038). CONCLUSION: This study shows that there is some evidence of a beneficial effect of rosuvastatin in terms of reduction of AF occurrence in patients with HF. Larger populations are needed to provide a definite answer to the question. ClinicalTrials.gov Identifier: NCT00336336.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Inflammation as a risk factor for atrial fibrillation
Aviles, R. J., Martin, D. O., Apperson-Hansen, C., Houghtaling, P. L., Rautaharju, P., Kronmal, R. A., Tracy, R. P., Van Wagoner, D. R., Psaty, B. M., Lauer, M. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103131.70301.4f · Cited by 1,425
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
Valsartan for prevention of recurrent atrial fibrillation
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805710 · Cited by 441
Ducharme, A., Swedberg, K., Pfeffer, M. A., Cohen-Solal, A., Granger, C. B., Maggioni, A. P., Michelson, E. L., McMurray, J. J. V., Olsson, L., Rouleau, J. L., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.06.036 · Cited by 352 · cited 2×
“ECGs was performed, being AF occurrence defined when reported as an adverse event in Val-HeFT(22) and with a specific case report form, but used just at the final or closing visit of the study in the CHARM trial.(23) In an analysis of the SOLVD trial, conducted in a limited number of patients, AF episodes occurred in…”
BackgroundResultKühlkamp, V., Schirdewan, A., Stangl, K., Homberg, M., Ploch, M., & Beck, O. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00693-8 · Cited by 256
Cited by
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C. D., Worthington, H. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub3 · Cited by 630
S. Antonopoulos, A., Margaritis, M., Lee, R., Channon, K., & Antoniades, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799504803 · Cited by 432
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C. D., Worthington, H. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003177.pub4 · Cited by 405
Metadata
- Authors
- Maggioni, A. P., Fabbri, G., Lucci, D., Marchioli, R., Franzosi, M. G., Latini, R., Nicolosi, G. L., Porcu, M., Cosmi, F., Stefanelli, S., Tognoni, G., Tavazzi, L., & on behalf of the GISSI-HF Investigators
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08-30
- Volume
- 30
- Issue
- 19
- Pages
- 2327-2336
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2062449826
- Cited by
- 100
- References
- 8
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehp357
- The paper
- Maggioni, A. P., Fabbri, G., Lucci, D., Marchioli, R., Franzosi, M. G., Latini, R., Nicolosi, G. L., Porcu, M., Cosmi, F., Stefanelli, S., Tognoni, G., Tavazzi, L., & on behalf of the GISSI-HF Investigators. (2009). Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehp357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.